Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

175 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R; ADAPT Investigator Study Group. Howard JF Jr, et al. Among authors: bilinska m. Lancet Neurol. 2021 Jul;20(7):526-536. doi: 10.1016/S1474-4422(21)00159-9. Lancet Neurol. 2021. PMID: 34146511 Clinical Trial.
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
Howard JF Jr, Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A, Beydoun S, Garrido FJRR, Piehl F, Rottoli M, Van Damme P, Vu T, Evoli A, Freimer M, Mozaffar T, Ward ES, Dreier T, Ulrichts P, Verschueren K, Guglietta A, de Haard H, Leupin N, Verschuuren JJGM; Efgartigimod MG Study Group. Howard JF Jr, et al. Among authors: bilinska m. Neurology. 2019 Jun 4;92(23):e2661-e2673. doi: 10.1212/WNL.0000000000007600. Epub 2019 May 22. Neurology. 2019. PMID: 31118245 Free PMC article. Clinical Trial.
[Seronegative myasthenia gravis].
Bilińska M. Bilińska M. Pol Merkur Lekarski. 2002 Jan;12(67):49-53. Pol Merkur Lekarski. 2002. PMID: 11957803 Polish.
An open-label study to evaluate the safety, tolerability and efficacy of rivastigmine in patients with mild to moderate probable Alzheimer's disease in the community setting.
Bilikiewicz A, Opala G, Podemski R, Puzyński S, Łapin J, Sołtys K, Ochudło S, Barcikowska M, Pfeffer A, Bilińska M, Paradowski B, Parnowski T, Gabryelewicz T. Bilikiewicz A, et al. Among authors: bilinska m. Med Sci Monit. 2002 Feb;8(2):PI9-15. Med Sci Monit. 2002. PMID: 11859291 Clinical Trial.
[Thymectomy in myasthenia gravis].
Rzyman W, Skokowski J, Marjański T, Walczak A, Szymanowska A, Bilinska M. Rzyman W, et al. Among authors: bilinska m. Pol Merkur Lekarski. 2005 Jan;18(103):41-4. Pol Merkur Lekarski. 2005. PMID: 15859545 Polish.
Neuropsychological assessment in myasthenia gravis.
Sitek EJ, Bilińska MM, Wieczorek D, Nyka WM. Sitek EJ, et al. Among authors: bilinska mm. Neurol Sci. 2009 Feb;30(1):9-14. doi: 10.1007/s10072-008-0001-y. Epub 2009 Jan 16. Neurol Sci. 2009. PMID: 19148573
175 results